Truway Health, Inc. clinical trials
The registry lists 16 studies whose lead sponsor is Truway Health, Inc.. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 5, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 16studies on the registry
- 16open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Truway Health, Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 7 programmes
Each counted once: 7 with a study Truway Health, Inc. leads registered in the last two years.
5 from the earlier phases, besides the phase-3 view.
| Programme | Main condition | ||||
|---|---|---|---|---|---|
| NaltrexonePhase 2 · 1 live · Obesity · primary completion Oct 2034 | Obesity | Phase 2 | 1 / 1 | Oct 2025 | Oct 2034 est. |
| |||||
| Skin Cell DipPhase 2 · 1 live · primary completion Oct 2031 | — | Phase 2 | 1 / 1 | Oct 2025 | Oct 2031 est. |
Read from the registry as written: no join or match was needed. | |||||
| Stem Cell DipPhase 2 · 1 live · primary completion Oct 2031 | — | Phase 2 | 1 / 1 | Oct 2025 | Oct 2031 est. |
Read from the registry as written: no join or match was needed. | |||||
| Combination Regenerative TherapyEarly phase 1 · 1 live · Hearing Loss, Noise-Induced · primary completion Mar 2097 | Hearing Loss, Noise-Induced | Early phase 1 | 1 / 1 | Mar 2026 | Mar 2097 est. |
Read from the registry as written: no join or match was needed. | |||||
| Investigational Regenerative Pharmacologic TherapyEarly phase 1 · 1 live · Hearing Loss, Noise-Induced · primary completion Mar 2097 | Hearing Loss, Noise-Induced | Early phase 1 | 1 / 1 | Mar 2026 | Mar 2097 est. |
Read from the registry as written: no join or match was needed. | |||||
2 more — sign in to see them all, free: with every programme, filter by condition or phase and sort by first study or primary completion.
Companies developing a programme in the same conditions as Truway Health, Inc.’s (3 conditions its studies of the last two years are mainly about), ranked by how directly they meet: a programme tested against the other’s drug, read from the study’s arms; then the conditions where both are in phase 3; then the conditions shared. Size plays no part.
- Eli Lilly and Company2 conditions shared: Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic
- AstraZeneca2 conditions shared: Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic
- Jiangsu HengRui Medicine Co., Ltd.2 conditions shared: Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic
- Hoffmann-La Roche2 conditions shared: Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic
- Qilu Pharmaceutical Co., Ltd.2 conditions shared: Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic
| Company | Conditions shared | Their phase 3 there | Where they meet, by arms |
|---|---|---|---|
| Eli Lilly and Company9 programmes in shared conditions | 2Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic | dulaglutide, retatrutide, orforglipron | no study of one against the other’s drug |
| AstraZeneca9 programmes in shared conditions | 2Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic | dapagliflozin, elecoglipron, lenbelintide +1 | no study of one against the other’s drug |
| Jiangsu HengRui Medicine Co., Ltd.7 programmes in shared conditions | 2Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic | SHR-3167, ribupatide | no study of one against the other’s drug |
| Hoffmann-La Roche6 programmes in shared conditions | 2Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic | enicepatide | no study of one against the other’s drug |
| Qilu Pharmaceutical Co., Ltd.4 programmes in shared conditions | 2Diabetes Mellitus, Type 2, Lupus Erythematosus, Systemic | QLG1091 | no study of one against the other’s drug |
108 more companies — sign in to see them all, free.
“Registry” is the highest phase of Truway Health, Inc.’s own registered studies; Truway Health, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Truway Health, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
1 of Truway Health, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- 1AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 16 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now16100%
Over the years
- 25
- 1126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Truway Health, Inc..
- Truway Health, Inc.16 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 16 of 16.
- Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care SettingsEnrolling by invitationNCT07214896Phase 2
- Healthcare Integrity & Anti-Fraud EnforcementEnrolling by invitationNCT07217730
- Truway Diagnostic Tools in Primary CareEnrolling by invitationNCT07209527Early Phase 1
- TruVascular Access - Ultrasound-Guided Vascular Access StudyEnrolling by invitationNCT07798427Not applicable
- Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access StudyEnrolling by invitationNCT07788040
- Multimodal Digital Biomarker Prediction of Acute Clinical DeteriorationEnrolling by invitationNCT07817550
- Multimodal Physiologic State Intelligence StudyEnrolling by invitationNCT07814118
- Clinical Time and Temporal Dynamics Study (CLIN-TIME)Enrolling by invitationNCT07812831
- Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)Enrolling by invitationNCT07805044
- Federated Learning for Point-of-Care Cardiac UltrasoundEnrolling by invitationNCT07800962
- NeuroFinance Human Stress Trial During Financial and Informational VolatilityEnrolling by invitationNCT07622589
- A Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian SurfaceEnrolling by invitationNCT07546461
- Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)Enrolling by invitationNCT07221565Phase 1/2
- Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing LossEnrolling by invitationNCT07472023Early Phase 1
- Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity VerificationEnrolling by invitationNCT07382804Not applicable
- Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)Enrolling by invitationNCT07321028Early Phase 1